United Therapeutics Corporation (UTHR)
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
UTHR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.63B
- P/E (TTM)
- 20.94
- Forward P/E
- 17.44
- EPS (TTM)
- $26.49
- Dividend yield
- None
- 52-week range
- 455.63 – 614.23
- Day range
- 551.77 – 563.11
- Volume / Avg
- 367.68K / 702.78K
- Beta
- —
- Shares outstanding
- 42.59M
52-week range
UTHR stock today
United Therapeutics (UTHR) closed at $554.73 on Nov 20, down 0.78% (-$4.37), versus the S&P 500's 3.70% decline. Shares are 9.7% below their 52-week high of $614.23, set on Nov 4, 2026 and 21.8% above the 52-week low of $455.63, in the middle of the past year's range. UTHR is up 13.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 16.8%.
At 20.9x trailing earnings, United Therapeutics trades above the peer-group median of 15.0x. Its forward P/E of 17.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About United Therapeutics
Company profileUnited Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
- Headquarters
- Silver Spring, MD
- Employees
- 1,400
- IPO year
- 1999
- Website
- unither.com
Financial highlights
Full financialsIn fiscal 2025, United Therapeutics generated $3.18 billion in revenue, up 10.6% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $1.33 billion (+11.7% year over year), for a net margin of 41.9% versus a median of 37.6% in the prior 5 years. Gross margin was 87.9% (down from 89.2%) and operating margin 46.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Growth | +10.61% | +23.63% | +20.20% | +14.88% | +13.63% |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$687.14+23.87%
- Strong buy 3
- Buy 9
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $5.71 vs $5.85
- Surprise
- -2.39%
UTHR news
All UTHR news- United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- United Therapeutics Prepares for TYVASO Expansion After $833 Million QuarterNasdaq
- SGIOY or UTHR: Which Is the Better Value Stock Right Now?Nasdaq
- United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Noteworthy ETF Outflows: MDY, FTI, UTHR, ATINasdaqMDY, FTI, UTHR, ATI
- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesNasdaqLQDA, UTHR, COLL, AMRX
- MannKind anticipates $1B in revenue from United Therapeutics deal from 2027-2030 as it targets Q4 profitabilitySeeking AlphaMNKD, UTHR
- What United Therapeutics (UTHR) Said on Its Q3 Earnings CallNasdaq
United Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs UTHR |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs UTHR |
| ALNYAlnylam Pharmaceuticals Inc. | 143.82 | -2.71% | $19.26B | vs UTHR |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs UTHR |
| ASNDAscendis Pharma A/S | 252.73 | -1.26% | $16.58B | vs UTHR |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs UTHR |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs UTHR |
| BBIOBridgeBio Pharma Inc. | 76.03 | -2.75% | $14.81B | vs UTHR |
Indexes, lists and sector
United Therapeutics stock FAQ
What is United Therapeutics's stock price today?
UTHR last traded at $554.73 as of Nov 20, 4:00 PM EST, down 0.78% on the day. Prices are delayed at least 15 minutes.
Does United Therapeutics pay a dividend?
No. United Therapeutics does not currently pay a regular cash dividend.
What is UTHR's P/E ratio?
UTHR trades at a trailing P/E ratio of 20.94 and a forward P/E of 17.44, compared with a median of 15.0 for its closest peers.
Who is United Therapeutics's CEO?
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. is the chief executive officer of United Therapeutics Corporation, which has about 1,400 employees.
Has UTHR ever split its stock?
Yes. The most recent UTHR stock split was a 2-for-1 split on Sep 23, 2009.
What is the UTHR 52-week high?
The 52-week high for UTHR is $614.23 and the 52-week low is $455.63. The stock is currently 9.7% below its high.